Exchange: NASDAQ·Updated 01:44 PM EDT
Upcoming Earnings: Q2 '26

Reports: Aug 11Pre-Market

Estimated EPS

$0.02

Estimated Rev

$16.21M

$FENC Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.01 • Reported revenue of $15.11M • Fennec Pharmaceuticals anticipates its cash, cash equivalents, and projected PEDMARK revenues will be sufficient to fund its business based on its current operating plan throughout 2026, positioning for sustained growth.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q2 '26
$0.02
--
--
N/A
Q1 '26
-$0.04
$0.01
122.81%
BEAT
Q4 '25
$0.04
-$0.17
-503.03%
MISSED
Q3 '25
-$0.02
-$0.02
9.09%
BEAT
Q2 '25
-$0.03
-$0.11
-223.53%
MISSED

Advertisement|Remove ads.